Dr. Mattapally working on development of universal human iPS cells by CRISPR-cas9 mediated Knockout MHC class I and MHC class II expression. Then differentiation of these iPS cells into three lineages such as cardiomyocytes (iPSC-CM), endothelial cells (iPSC-EC) and smooth muscle cells (iPSC-SMC). This tri-lineage derived engineered myocardial tissue will be used to treat myocardial infarction and its therapy application.

Dr. Saidulu Mattapally Research mainly focused on Stem cells, cell differentiation and dedifferentiation, Congenital Heart Disease, Diabetic cardiomayopathy, Pharmacology, Molecular Genetics.